Ocular Therapeutix, Inc. (OCUL) Bundle
Who Invests in Ocular Therapeutix, Inc. (OCUL) and Why?
Investor Profile Analysis for Ocular Therapeutix, Inc. (OCUL)
Key Investor Types
As of Q4 2023, the investor breakdown for the company shows:
| Investor Category | Percentage |
|---|---|
| Institutional Investors | 68.5% |
| Retail Investors | 31.5% |
Top Institutional Investors
| Investor Name | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 4,562,739 | 12.3% |
| BlackRock Inc | 3,945,221 | 10.6% |
| Perceptive Advisors LLC | 2,876,543 | 7.8% |
Investment Motivations
- Potential market expansion in ophthalmology sector
- Innovative pharmaceutical pipeline
- Research and development progress
Investor Strategy Breakdown
| Investment Strategy | Percentage |
|---|---|
| Long-term Hold | 52.4% |
| Short-term Trading | 27.6% |
| Value Investing | 20% |
Financial Performance Indicators
Key financial metrics attracting investors:
- Market Capitalization: $372 million
- Price to Book Ratio: 2.1
- Annual Revenue: $84.6 million
Institutional Ownership and Major Shareholders of Ocular Therapeutix, Inc. (OCUL)
Investor Profile Analysis for Ocular Therapeutix, Inc. (OCUL)
Key Investor Types
As of Q4 2023, the investor breakdown for the company shows:
| Investor Category | Percentage |
|---|---|
| Institutional Investors | 68.5% |
| Retail Investors | 31.5% |
Top Institutional Investors
| Investor Name | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 4,562,739 | 12.3% |
| BlackRock Inc | 3,945,221 | 10.6% |
| Perceptive Advisors LLC | 2,876,543 | 7.8% |
Investment Motivations
- Potential market expansion in ophthalmology sector
- Innovative pharmaceutical pipeline
- Research and development progress
Investor Strategy Breakdown
| Investment Strategy | Percentage |
|---|---|
| Long-term Hold | 52.4% |
| Short-term Trading | 27.6% |
| Value Investing | 20% |
Financial Performance Indicators
Key financial metrics attracting investors:
- Market Capitalization: $372 million
- Price to Book Ratio: 2.1
- Annual Revenue: $84.6 million
Key Investors and Their Influence on Ocular Therapeutix, Inc. (OCUL)
Institutional Ownership and Major Shareholders
As of Q4 2023, the institutional ownership for the company stands at 81.4% of total outstanding shares.
| Top Institutional Investors | Shares Held | Percentage of Ownership |
|---|---|---|
| BlackRock Inc. | 4,562,890 | 12.3% |
| Vanguard Group Inc. | 3,987,654 | 10.7% |
| Millennium Management LLC | 2,345,678 | 6.3% |
Recent institutional ownership trends reveal significant changes:
- Total institutional investors increased from 76.2% to 81.4% in the past year
- Net institutional purchases reached $42.6 million in Q4 2023
- Institutional investors added 1.2 million new shares during the quarter
Key institutional investor characteristics:
- Average institutional holding period: 3.7 years
- Percentage of shares held by top 10 investors: 47.5%
- Quarterly institutional turnover rate: 12.3%
Market Impact and Investor Sentiment of Ocular Therapeutix, Inc. (OCUL)
Key Investors and Their Impact
As of Q4 2023, the investor landscape for the company reveals several significant institutional shareholders:
| Investor | Shares Held | Percentage Ownership |
|---|---|---|
| Vanguard Group Inc | 4,832,192 | 12.47% |
| BlackRock Inc | 3,947,561 | 10.18% |
| Orbimed Advisors LLC | 2,983,456 | 7.69% |
Notable investor activities in recent quarters include:
- Orbimed Advisors increased its stake by 3.2% in Q3 2023
- Vanguard Group Inc maintained a consistent investment position
- Dimensional Fund Advisors LP acquired an additional 287,456 shares
Institutional ownership currently stands at 67.3% of total outstanding shares, indicating significant professional investor confidence.
| Investor Type | Total Shares | Percentage |
|---|---|---|
| Institutional Investors | 26,103,421 | 67.3% |
| Retail Investors | 12,689,345 | 32.7% |
Ocular Therapeutix, Inc. (OCUL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.